HIGHBuilt-in & outside partyPipeline
nomlabofusp
“10-K Item 1A: 'our business is currently wholly dependent on our successful clinical development, regulatory approval and commercialization of nomlabofusp'”
LRMR · Concentration risk · 10-K extracted
Larimar Therapeutics (LRMR) concentration risks
Updated
The most significant concentration Larimar Therapeutics discloses is nomlabofusp, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Larimar Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-08-23Larimar Therapeutics carries the concentration profile typical of a clinical-stage biotech: the company's business is currently wholly dependent on the successful clinical development, regulatory approval, and commercialization of a single product candidate, nomlabofusp — a high-share exposure with a mixed character, since a single-asset pipeline is simultaneously the entire basis for the investment thesis and the sole point of failure. No other product, customer, geographic, or supplier concentration is disclosed alongside it, which means there is no diversification anywhere in the business to offset a setback in this one program. Practically, that means clinical trial results, regulatory decisions, or manufacturing issues tied specifically to nomlabofusp would move the entire company's value, not just one segment of it — there is no other approved or late-stage asset to cushion a negative outcome. This is a common and expected structure for a pre-commercial biotech at this stage, but it does mean the risk here is binary in nature: the size and character of the exposure move together, and there is nothing in this disclosure set to diversify against.
For the engine’s reasoning on LRMR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| LRMR● | Larimar Therapeutics, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.